ArticleJournal of gastroenterology2026
Regulatory mechanism of the RNF168-SCCA1-MYH9 signaling axis in the response of ulcerative colitis.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe potential function of E3 ubiquitin ligase RNF168 in inflammatory processes remains largely unexplored. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation and epithelial damage of the intestinal mucosa. The pathophysiology of UC is complex, and its mechanisms remain incompletely understood. This study explores the role of RNF168 in the pathogenesis of experimental colitis.
methodsRNF168-knockout murine models were employed. The functional impact of RNF168 was determined by assessing colitis severity and susceptibility in these mice through a comprehensive evaluation of disease activity index, histological scoring, and pro-inflammatory cytokine levels. The molecular mechanism was explained using co-immunoprecipitation combined with mass spectrometry to identify and confirm downstream effectors.
resultsWe identified RNF168 as a susceptibility gene for colonic inflammation in mouse models and cell lines. RNF168 downregulation in colonic inflammation reduces SCCA1 ubiquitination, leading to SCCA1 accumulation. Increased SCCA1 contribute to inflammation by suppresses the MYH9-p53 signaling pathway, subsequently reduces the expression of p53 and phosphorylated p53 (p-p53), thereby exacerbating the inflammatory response. Administration of the small-molecule SCCA1 inhibitor 1-PPA alleviated colonic inflammation pathology. Our findings reveal a novel ubiquitination-dependent pathway and identify SCCA1 as a promising therapeutic target for colonic inflammation.
conclusionsOur findings reveal a novel ubiquitination-dependent pathway in experimental colitis pathogenesis and identify SCCA1 as a promising therapeutic target for colitis. Elucidating these mechanisms opens avenues for developing therapies targeting inflammatory responses in UC.
Indexed as
Identifiers
42307721What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.